Report interim data from the ORIC-101 and nab-paclitaxel combination trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Report interim safety, efficacy, and translational data from ongoing combination trial with nab-paclitaxel in the first half of 2021”
What we found
Evidence strength A What the grades mean
The company reported initial data from the ORIC-101 and nab-paclitaxel combination trial in June 2021, which falls within the first half of 2021.
-
A Oric Pharmaceuticals, Inc. 10-Q filed 2021-08-10
“In June 2021, we reported initial data from our ongoing Phase 1b study evaluating ORIC-101, in combination with nab-paclitaxel, in advanced solid tumors.” ✓ confirmed on the page
Market reaction: the shares moved +16.1% against the S&P 500 over the three sessions around the disclosure (9 Aug 2021 to 12 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- interim clinical trial data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Oric Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ORIC-021533 · Corrections policy